Top Investments: Vishay Intertechnology (NYSE:VSH), Bancolombia S.A. (NYSE:CIB), Lloyds Banking Group plc (NYSE:LYG), Macrocure (NASDAQ:MCUR), Gyrodyne Co. of America Inc. (NASDAQ:GYRO)


Vishay Intertechnology Inc. (NYSE:VSH) shares moved down -3.34% in last trading session and ended the day at $9.55. VSH Gross Margin is 24.20% and its has a return on assets of 3.50%. Vishay Intertechnology Inc. (NYSE:VSH) quarterly performance is -26.08%.

Vishay Intertechnology, Inc. is a global manufacturer and supplier of discrete semiconductors and passive components. The Company supports the microprocessor chips and other integrated circuits (ICs) that coordinate and control the functions of electronic devices and equipment. The Company offers its customers access to electronic component product lines of any manufacturer in the United States, Europe and Asia.

Vishay Intertechnology Inc. (NYSE:VSH) announced a cash dividend payment of $0.06 per share is scheduled to be paid on September 24, 2015. Shareholders who purchased VSH prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 7th quarter that VSH has paid the same dividend. At the current stock price of $10.05, the dividend yield is 2.39%.

Bancolombia S.A. (NYSE:CIB) ended the last trading day at $32.88. Company weekly volatility is calculated as 4.85% and price to cash ratio as 1.58. Bancolombia S.A. (NYSE:CIB) showed a weekly performance of 9.24%.

Bancolombia S.A. is a commercial bank. The Bank provides financial products and services to a diversified individual, corporate and government customer base throughout Colombia, Latin America and the Caribbean region. The Bank and its subsidiaries offer savings and investment, financing, mortgage banking, factoring, financial and operating leases, capital markets, eTrading, cash management, foreign currency, insurance, investment banking, and trust and fiduciary services.

Bancolombia S.A. (NYSE:CIB) was upgraded by Zacks from a “hold” rating to a “buy” rating in a report issued on Thursday, MarketBeat Ratings reports. The firm presently has a $36.00 target price on the stock. Zacks‘s target price suggests a potential upside of 10.77% from the stock’s current price.

On 01 September, Lloyds Banking Group plc (NYSE:LYG) shares moved down -2.93% and was closed at $4.64. LYG EPS growth in last 5 year was -26.60%. Lloyds Banking Group plc (NYSE:LYG) year to date (YTD) performance is 1.92%.

Lloyds Banking Group plc is engaged in providing financial services to individual and business customers in the United Kingdom and in certain locations overseas. The Company offers retail and commercial banking, and long-term savings, protection and investment. It operates through five segments: Retail, Commercial Banking, Consumer Finance, Insurance and TSB Banking Group plc (TSB).

On 24 August, Lloyds Banking Group plc (NYSE:LYG) said that, George Osborne aims to sell the government’s stake in Lloyds Banking Group within a year, prompting concern that he is rushing to privatise state-backed lenders at the expense of taxpayers.

Macrocure Ltd. (NASDAQ:MCUR) shares moved up 7.84% in last trading session and ended the day at $3.30. MCUR has a return on assets of -68.20%. Macrocure Ltd. (NASDAQ:MCUR) quarterly performance is -73.19%.

MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is an advanced wound care (AWC) therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process.

On 19 August, Macrocure Ltd. (NASDAQ:MCUR) announced that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board for CureXcell® – the Company’s lead product candidate in its Phase 3 pivotal clinical study (MC-105) for venous leg ulcers (VLU) – determined that this study is not expected to meet its primary endpoint.

Gyrodyne Co. of America Inc. (NASDAQ:GYRO) caters to the Financial space. Its weekly performance is 966.32%. On the last day of trading company shares ended up $30.39. Gyrodyne Co. of America Inc. (NASDAQ:GYRO) distance from 50-day simple moving average (SMA50) is 947.01%.

Gyrodyne, LLC, formerly Gyrodyne Company of America, Inc., is a self-managed and self-administered real estate investment trust (REIT). The Company’s primary business is the investment in and the acquisition, ownership and management of a geographically diverse portfolio of medical office, industrial and development of industrial and residential properties located in the Northeast region of the United States. The Company’s properties are generally located in markets, including Suffolk and Westchester counties in New York and Fairfax, Virginia in the metro-Washington D.C area.

Gyrodyne Co. of America Inc. (NASDAQ:GYRO) announced the completion of the previously announced merger of Gyrodyne Company of America, Inc. (the “Corporation”) and Gyrodyne Special Distribution, LLC (“GSD”) into Gyrodyne.


Leave a Reply

Your email address will not be published. Required fields are marked *